This panel brings together leading researchers to explore how health economics can inform policy design in the context of the climate crisis. Rather than proposing ...

In our latest insight, we reflect on what we’re seeing in the region, from Saudi Arabia’s Vision 2030 to the UAE’s push for innovation and value in healthcare.

Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually and impose economic costs exceeding $150 billion by ...

This is the second in our series of Insights considering the implications of President Trump’s Executive Order on ‘Most Favoured Nation’ drug pricing. We know ...

As healthcare systems strive to allocate resources efficiently, the use of economic evaluation metrics like Quality-Adjusted Life Years (QALYs) has become increasingly important.

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés Pichon-Riviere, Federico Augustovski, and ...

This is the second in our series of Insights considering the implications of President Trump’s Executive Order on ‘Most Favoured Nation’ drug pricing. We know that pegging US drug prices to the rest ...

OHE Expert Profile Hugh Gravelle Hugh Gravelle – Centre for Health Economics, University of York ...